Walvax BioTech
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meni… Read more
Walvax BioTech (300142) - Total Assets
Latest total assets as of September 2025: CN¥13.25 Billion CNY
Based on the latest financial reports, Walvax BioTech (300142) holds total assets worth CN¥13.25 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Walvax BioTech - Total Assets Trend (2007–2024)
This chart illustrates how Walvax BioTech’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Walvax BioTech - Asset Composition Analysis
Current Asset Composition (December 2024)
Walvax BioTech's total assets of CN¥13.25 Billion consist of 48.0% current assets and 52.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 25.6% |
| Accounts Receivable | CN¥2.49 Billion | 16.9% |
| Inventory | CN¥752.59 Million | 5.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.49 Billion | 10.1% |
| Goodwill | CN¥33.66 Million | 0.2% |
Asset Composition Trend (2007–2024)
This chart illustrates how Walvax BioTech's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Walvax BioTech's current assets represent 48.0% of total assets in 2024, an increase from 47.2% in 2007.
- Cash Position: Cash and equivalents constituted 25.6% of total assets in 2024, up from 12.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 9.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 16.9% of total assets.
Walvax BioTech Competitors by Total Assets
Key competitors of Walvax BioTech based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Walvax BioTech - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Walvax BioTech generates 0.19x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Walvax BioTech generates $ 0.97 in net profit.
Walvax BioTech - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.52 | 3.10 | 3.36 |
| Quick Ratio | 3.20 | 2.72 | 3.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.23 Billion | CN¥ 5.01 Billion | CN¥ 3.36 Billion |
Walvax BioTech - Advanced Valuation Insights
This section examines the relationship between Walvax BioTech's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.97 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | -5.5% |
| Total Assets | CN¥14.72 Billion |
| Market Capitalization | $2.39 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Walvax BioTech's assets below their book value (0.16 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Walvax BioTech's assets decreased by 5.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Walvax BioTech (2007–2024)
The table below shows the annual total assets of Walvax BioTech from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥14.72 Billion | -5.55% |
| 2023-12-31 | CN¥15.59 Billion | +1.70% |
| 2022-12-31 | CN¥15.33 Billion | +12.09% |
| 2021-12-31 | CN¥13.67 Billion | +41.87% |
| 2020-12-31 | CN¥9.64 Billion | +37.34% |
| 2019-12-31 | CN¥7.02 Billion | -3.03% |
| 2018-12-31 | CN¥7.24 Billion | +23.16% |
| 2017-12-31 | CN¥5.88 Billion | -7.08% |
| 2016-12-31 | CN¥6.32 Billion | +1.06% |
| 2015-12-31 | CN¥6.26 Billion | +4.86% |
| 2014-12-31 | CN¥5.97 Billion | -2.74% |
| 2013-12-31 | CN¥6.14 Billion | +37.88% |
| 2012-12-31 | CN¥4.45 Billion | +47.99% |
| 2011-12-31 | CN¥3.01 Billion | +0.69% |
| 2010-12-31 | CN¥2.99 Billion | +673.44% |
| 2009-12-31 | CN¥386.12 Million | +27.90% |
| 2008-12-31 | CN¥301.90 Million | +38.79% |
| 2007-12-31 | CN¥217.52 Million | -- |